Showing results (211-220 of 295) with videos related to

Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerHope S Rugo, Jean-Pierre Delord, Seock-Ah Im, et al.
NPJ Precision Oncology|June 3, 2026
Longitudinal evaluation of serial ctDNA kinetics using joint modeling in patients with metastatic breast cancerChristopher Pretz, Jesús Fuentes-Antrás, Sasha Main, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid TumorsGiuseppe Curigliano, Hans Gelderblom, Nicolas Mach, et al.
Journal of Clinical Pharmacology|December 18, 2023
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)Elena Garralda, Do Youn Oh, Antoine Italiano, et al.
NPJ Precision Oncology|June 15, 2026
Longitudinal validation of ENLIGHT, an AI predictor of immunotherapy response and resistance, in pan-cancer cohortsChangsu L Park, Gal Dinstag, Carlos D Holanda Lopes, et al.
European Urology Oncology|December 8, 2020
Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell CancerJoão Lobo, Ricardo Leão, Ad J M Gillis, et al.
Cancer|February 16, 2019
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicitiesYada Kanjanapan, Daphne Day, Lisa Wang, et al.
Cancer Research Communications|October 17, 2025
The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)Mamta Parikh, Nataliya V Uboha, Naoko Takebe, et al.
Nature Communications|February 6, 2024
Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patientScott C Lien, Dalam Ly, S Y Cindy Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Robin Kate Kelley, Anthony W Tolcher, et al.
Pageof 30